A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors

Arthritis and Rheumatology

Volumn 66, Issue 7, 2014, Pages 1693-1704

  Genovese, Mark C ^a   Greenwald, Maria ^b   Cho, Chul Soo ^c   Berman, Alberto ^d   Jin, Ling ^e   Cameron, Gregory S ^e   Benichou, Olivier ^e   Xie, Li ^e   Braun, Daniel ^e   Berclaz, Pierre Yves ^e   Banerjee, Subhashis ^e,f  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Desert Medical Advances   (United States)

^c The Catholic University of Korea   (South Korea)

^d Centro Medico Privado de Reumatologia   (Argentina)

^e ELI LILLY AND COMPANY   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; IXEKIZUMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-17; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903478179     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38617     Document Type: Article

References (33)

1. McInnes IB,. Cytokines. In:, Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS, editors. Kelley's textbook of rheumatology. 9th ed. Philadelphia: Elsevier; 2009. p. 367-77.
2. Chao CC, Chen SJ, Adamopoulos IE, Davis N, Hong K, Vu A, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011; 44: 243-52.
3. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-9.
4. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62: 929-39.
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
6. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
7. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 1114-23.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F,. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502.
10. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995: 38: 44-8.
11. Van Gestel AM, Haagsma CJ, van Riel PL,. Validation of rheumatoid arthritis criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
12. Villaverde V, Balsa A, Cantalejo M, Fernandez-Prada M, Madero MR, Munoz-Fernandez S, et al. Activity indices in rheumatoid arthritis. J Rheumatol 2000; 27: 2576-81.
13. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J,. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001; 28: 892-903.
14. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: R1063-71.
15. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
16. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
17. Fries JF, Spitz PW, Young DY,. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-93.
18. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. August 9, 2006. URL: http://ctep.cancer. gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
19. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
20. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2012; 72: 863-9.
21. Pavelka K, Chon Y, Newmark R, Erondu N, Lin SL,. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate [abstract]. Arthritis Rheum 2012; 64 Suppl: S362.
22. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study [published erratum appears in Arthritis Rheum 2010;62:3518]. Arthritis Rheum 2008; 58: 964-75.
23. Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
24. Mertens M, Singh JA,. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36: 1118-25.
25. Kerensky TA, Gottlieb AB, Yaniv S, Au SC,. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf 2012; 11: 121-39.
26. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al, for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-9.
27. Navarro-Millan I, Singh JA, Curtis JR,. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012; 34: 788-802.
28. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF,. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005; 44: 61-6.
29. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
30. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 547-54.
31. Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 2012; 42: 131-9.
32. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL,. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 2011; 13: R126.
33. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71: 1741-8.